This cohort study investigates the risks of mortality and adverse cardiovascular and kidney outcomes among individuals with type 2 diabetes taking tirzepatide vs glucagon-like peptide 1 receptor agonists. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.